- Home
- SIF vs EQ Comparison
SIF vs EQ Comparison
Compare SIF & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SIF
- EQ
- Stock Information
- Founded
- SIF 1913
- EQ 2017
- Country
- SIF United States
- EQ United States
- Employees
- SIF N/A
- EQ N/A
- Industry
- SIF Office Equipment/Supplies/Services
- EQ Biotechnology: Pharmaceutical Preparations
- Sector
- SIF Industrials
- EQ Health Care
- Exchange
- SIF Nasdaq
- EQ Nasdaq
- Market Cap
- SIF 22.6M
- EQ 24.8M
- IPO Year
- SIF N/A
- EQ 2018
- Fundamental
- Price
- SIF $3.65
- EQ $0.66
- Analyst Decision
- SIF
- EQ Buy
- Analyst Count
- SIF 0
- EQ 2
- Target Price
- SIF N/A
- EQ $5.00
- AVG Volume (30 Days)
- SIF 4.7K
- EQ 166.1K
- Earning Date
- SIF 02-12-2025
- EQ 03-24-2025
- Dividend Yield
- SIF N/A
- EQ N/A
- EPS Growth
- SIF N/A
- EQ N/A
- EPS
- SIF N/A
- EQ N/A
- Revenue
- SIF $79,633,000.00
- EQ $45,914,000.00
- Revenue This Year
- SIF N/A
- EQ $4.77
- Revenue Next Year
- SIF N/A
- EQ N/A
- P/E Ratio
- SIF N/A
- EQ N/A
- Revenue Growth
- SIF 20.53
- EQ 7.70
- 52 Week Low
- SIF $2.90
- EQ $0.49
- 52 Week High
- SIF $5.96
- EQ $3.25
- Technical
- Relative Strength Index (RSI)
- SIF 50.40
- EQ 45.39
- Support Level
- SIF $3.57
- EQ $0.49
- Resistance Level
- SIF $3.89
- EQ $0.70
- Average True Range (ATR)
- SIF 0.12
- EQ 0.07
- MACD
- SIF 0.02
- EQ -0.00
- Stochastic Oscillator
- SIF 53.66
- EQ 60.50
About SIF SIFCO Industries Inc.
SIFCO Industries Inc is engaged in the production of forgings and machined components for the Aerospace and Energy, Defense and Commercial Space markets. Its processes and services include forging, heat-treating and machining. It serves original equipment manufacturers (OEM) as well as aftermarket customers. Its products are made of steel, stainless steel, titanium and aluminium and include OEM and aftermarket components for aircraft and industrial gas turbine engines, steam turbine blades, structural airframe components, aircraft landing gear components, aircraft wheels and brakes, critical rotating components for helicopters and industrial products. Substantial revenue is derived from North America as well as operates in Europe.
About EQ Equillium Inc.
Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.